NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

CVM

CVM announced the primary endpoint failed.

They spun the subset analysis as a win, it is not.

It does not matter if that subset was a predefined analysis. It is still not suitable for approval.

And even more so in this case where the subset can not even be clinically defined until after the decision to treat is made.

CVM and NWBO are doppleganglers. The only difference is LP is a sharp lawyer and stays quiet while Gert tweets out BS.

They are still in a race to see a paper published (or eve a true TLD PR). I am guessing neither in 2022.